

Press Release

Vienna, August 14, 2007

Initiation of Clinical Phase I Study for Topical Antibiotic

Vienna – Nabriva Therapeutics announced today commencement of a clinical phase I program for its topical pleuromutilin antibiotic BC-7013.

BC-7013 belongs to a series of proprietary Nabriva pleuromutilins, which have been designed by Nabriva's medicinal chemists to fulfill the specific requirements of a topical antibacterial agent. The clinical study is designed to evaluate safety and tolerability of BC-7013.

"This is the second pleuromutilin antibiotic Nabriva has moved into clinical trials since our inception 18 months ago, emphasising our view of the potential of this new antibiotic class", said Rodger Novak, Chief Operating Officer of Nabriva.

Nabriva's first pleuromutilin program to enter the clinic, BC-3205, is an oral agent with activity against gram positive and gram negative bacteria and atypicals. BC-3205 is currently in a multi-dose Phase I trial.

Pleuromutilin antibiotics are a novel clinically validated class of antibiotics that specifically inhibit bacterial protein synthesis. Their antibacterial profile covers resistant pathogens, including MRSA, that cause diseases such as respiratory tract and skin infections.

About Nabriva:

Nabriva Therapeutics GmbH, headquartered in Vienna is a biopharmaceutical company engaged in the discovery and development of innovative antibiotics addressing unmet medical need in the hospital and community setting. The company currently has two ongoing phase I programs based on the pleuromutilin class of antibiotics with additional preclinical stage compounds. All of Nabriva's programs are derived from compounds generated in-house through discovery activity that focuses on novel and differentiated anti-bacterial agents.

Nabriva Therapeutics was founded in January 2006 as a spin-out of Sandoz GmbH Kundl. The spin-out was led by Nomura Phase4 Ventures with a Series A financing of €42 million with a syndicate that included HBM Partners, GLSV, The Wellcome Trust and Novartis Venture Fund.

For more information please visit: www.nabriva.com.

Press contact:

Nabriva Therapeutics GmbH

Contact person: Rodger Novak, Managing Director and COO

Telephone: +43 (0)1 866 59 695; e-mail: rodger.novak@nabriva.com